title: [Factors affecting the response to erythropoiesis-stimulating agents].
abstract: Recombinant human erythropoietin (rHuEPO) has transformed the management chronic renal failure (CKD) and considerably improved the outcome of patients on regular chronic dialysis. However, a significant number of patients fail to respond to high of Erythropoiesis-stimulating agents (ESAs) and several causes of inadequate response to epoetin therapy have been identified. Some factors, such as gender, age, length of time on dialysis, type of dialysis and co-morbidities such as hemoglobinopathy, are not susceptible to clinical intervention. However, many other factors can be adjusted. Iron deficiency, whether functional or absolute, is the most common factor that limits the response to rHuEPO. Monitoring of iron parameters and a large use of iron supplementation result in an efficient epoetin response. Infection and inflammation have been shown to reduce responsiveness to ESAs by disrupting iron metabolism and increasing the release of pro-inflammatory cytokines that inhibit erythropoiesis. Increase dialysis dose is associated with improvements in anemia correction and reduced requirements for ESAs. Severe hyperparathyroidism and aluminum overload lead to a reduced number of responsive erythroid progenitor cells. Finally, a number of nutritional factors, such as deficiencies of carnitine, vitamin B12, folic acid, and vitamin C, are susceptible to alter erythropoiesis. Optimizing patient response to ESAs therefore requires consideration of many of well-established factors and is important for both patient outcomes and cost of treatment.
authors: Service de néphrologie et de transplantation rénale, hôpital Sud, CHU d'Amiens, avenue René-Laennec, 80054 Amiens 01, France.
authors: Maïté
authors: M
authors: Jauréguy
authors: Gabriel
authors: G
authors: Choukroun
mesh_terms: D000740:Anemia / Q000188:drug therapy* / Q000209:etiology*; D016207:Cytokines / Q000378:metabolism; D004920:Erythropoiesis / Q000187:drug effects; D004921:Erythropoietin / Q000627:therapeutic use*; D006801:Humans; D007249:Inflammation / Q000503:physiopathology; D000090463:Iron Deficiencies; D007676:Kidney Failure, Chronic / Q000150:complications*; D011994:Recombinant Proteins; D012842:Sarcoma Virus, Woolly Monkey; D014815:Vitamins / Q000378:metabolism
chemical_list: D016207:Cytokines; D011994:Recombinant Proteins; D014815:Vitamins; D004921:Erythropoietin